Seemi Khan

Company: Alkeus Pharmaceuticals, Inc.

Job title: Chief Medical Officer

Seminars:

Investigating the Opportunity for a New Oral Chemical Entity, Gildeuretinol, for the treatment of Geographic Atrophy Secondary to AMD 2:00 pm

Summarizing the gildeuretinol program and Alkeus’ efforts to understand mechanisms of disease Discussing results of SAGA, a 2-year, randomized, double-masked, placebo-controlled study Sharing next steps in the development pathway for gildeuretinolRead more

day: Conference Day Two